Effect of concomitant use of pitavastatin with neoadjuvant chemotherapy protocols in breast cancer patients: A randomized controlled clinical trial
Introduction: Preclinical studies have demonstrated the possible anticancer effects of statins, but the synergistic effect of concomitant statin use with standard chemotherapy protocols in patients with breast cancer has not yet been investigated. Aim: The current study aimed to evaluate the efficac...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-10-01
|
| Series: | Saudi Pharmaceutical Journal |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1319016422002031 |
| _version_ | 1811243424298303488 |
|---|---|
| author | Samar A. Dewidar Omar Hamdy Ahmed Eltantawy Mohamed El-Mesery Amal M. El Gayar Moetaza M. Soliman |
| author_facet | Samar A. Dewidar Omar Hamdy Ahmed Eltantawy Mohamed El-Mesery Amal M. El Gayar Moetaza M. Soliman |
| author_sort | Samar A. Dewidar |
| collection | DOAJ |
| description | Introduction: Preclinical studies have demonstrated the possible anticancer effects of statins, but the synergistic effect of concomitant statin use with standard chemotherapy protocols in patients with breast cancer has not yet been investigated. Aim: The current study aimed to evaluate the efficacy of concomitant pitavastatin use with neoadjuvant chemotherapy protocols in patients with breast cancer. Methods: This study was a randomized controlled clinical trial. A total of 70 adult female patients with pathologically-proven invasive breast cancer were randomized to receive or not receive pitavastatin (2 mg) oral tablets once daily concomitantly with standard neoadjuvant chemotherapy protocols for 6 months. The primary outcomes of this study were changes in tumor size and changes to the Ki67 index. In addition, secondary outcomes were changes in cyclin D1 and cleaved caspase-3 serum levels. This study was registered at ClinicalTrials.gov (Identifier: NCT04705909). Results: Patients in the pitavastatin group showed significantly higher median (IQR) reductions in tumor size [−19.8 (−41.5, 9.5)] compared to those in the control group [−5.0 (−15.5, 0.0), p = 0.0009]. The change in Ki67 from baseline to the end of therapy was similar between the two groups (p = 0.12). By the end of therapy, the cyclin D1 levels in the pitavastatin group were significantly decreased [median (IQR) change of − 10.0 (−20.2, −2.9) from baseline], whereas the control group showed an increase in cyclin D1 levels [14.8 (4.1, 56.4)]. The median (IQR) caspase−3 was elevated in the pitavastatin group 1.6 (0.2, 2.2), and decreased in the control group (−0.2 (−1.1, 0.0), p = 0.0002).Subgroup analysis of the pitavastatin group revealed that patients with positive human epidermal growth receptor 2 (HER2) had higher median (IQR) reductions in Ki67 [−35.0 (−70.0, −12.5)] than those with negative HER2 [2.5 (−15.0, 10.0), p = 0.04]. All patients who achieved a complete pathological response (n = 9) exhibited an HER2-neu positive receptor at baseline. Conclusion: Concomitant use of pitavastatin with standard neoadjuvant chemotherapy protocols may improve neoadjuvant chemotherapy responses in patients with breast cancer. |
| first_indexed | 2024-04-12T14:07:09Z |
| format | Article |
| id | doaj.art-08c910760fd84e89a9faa2ba57e999d2 |
| institution | Directory Open Access Journal |
| issn | 1319-0164 |
| language | English |
| last_indexed | 2024-04-12T14:07:09Z |
| publishDate | 2022-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Saudi Pharmaceutical Journal |
| spelling | doaj.art-08c910760fd84e89a9faa2ba57e999d22022-12-22T03:30:02ZengElsevierSaudi Pharmaceutical Journal1319-01642022-10-01301014861496Effect of concomitant use of pitavastatin with neoadjuvant chemotherapy protocols in breast cancer patients: A randomized controlled clinical trialSamar A. Dewidar0Omar Hamdy1Ahmed Eltantawy2Mohamed El-Mesery3Amal M. El Gayar4Moetaza M. Soliman5Clinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy, Mansoura University, Mansoura, EgyptSurgical Oncology Department, Oncology Center, Mansoura University, Mansoura University, Mansoura, EgyptMedical Oncology Unit, Oncology Center, Mansoura University, Mansoura, EgyptBiochemistry Department, Faculty of Pharmacy, Mansoura University, Mansoura, EgyptBiochemistry Department, Faculty of Pharmacy, Mansoura University, Mansoura, EgyptClinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt; Corresponding author at: Clinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy, Mansoura University, Mansoura 35516, EgyptIntroduction: Preclinical studies have demonstrated the possible anticancer effects of statins, but the synergistic effect of concomitant statin use with standard chemotherapy protocols in patients with breast cancer has not yet been investigated. Aim: The current study aimed to evaluate the efficacy of concomitant pitavastatin use with neoadjuvant chemotherapy protocols in patients with breast cancer. Methods: This study was a randomized controlled clinical trial. A total of 70 adult female patients with pathologically-proven invasive breast cancer were randomized to receive or not receive pitavastatin (2 mg) oral tablets once daily concomitantly with standard neoadjuvant chemotherapy protocols for 6 months. The primary outcomes of this study were changes in tumor size and changes to the Ki67 index. In addition, secondary outcomes were changes in cyclin D1 and cleaved caspase-3 serum levels. This study was registered at ClinicalTrials.gov (Identifier: NCT04705909). Results: Patients in the pitavastatin group showed significantly higher median (IQR) reductions in tumor size [−19.8 (−41.5, 9.5)] compared to those in the control group [−5.0 (−15.5, 0.0), p = 0.0009]. The change in Ki67 from baseline to the end of therapy was similar between the two groups (p = 0.12). By the end of therapy, the cyclin D1 levels in the pitavastatin group were significantly decreased [median (IQR) change of − 10.0 (−20.2, −2.9) from baseline], whereas the control group showed an increase in cyclin D1 levels [14.8 (4.1, 56.4)]. The median (IQR) caspase−3 was elevated in the pitavastatin group 1.6 (0.2, 2.2), and decreased in the control group (−0.2 (−1.1, 0.0), p = 0.0002).Subgroup analysis of the pitavastatin group revealed that patients with positive human epidermal growth receptor 2 (HER2) had higher median (IQR) reductions in Ki67 [−35.0 (−70.0, −12.5)] than those with negative HER2 [2.5 (−15.0, 10.0), p = 0.04]. All patients who achieved a complete pathological response (n = 9) exhibited an HER2-neu positive receptor at baseline. Conclusion: Concomitant use of pitavastatin with standard neoadjuvant chemotherapy protocols may improve neoadjuvant chemotherapy responses in patients with breast cancer.http://www.sciencedirect.com/science/article/pii/S1319016422002031Synergistic actionTumor responseKi67Hormone receptorCyclin D1Caspase-3 |
| spellingShingle | Samar A. Dewidar Omar Hamdy Ahmed Eltantawy Mohamed El-Mesery Amal M. El Gayar Moetaza M. Soliman Effect of concomitant use of pitavastatin with neoadjuvant chemotherapy protocols in breast cancer patients: A randomized controlled clinical trial Saudi Pharmaceutical Journal Synergistic action Tumor response Ki67 Hormone receptor Cyclin D1 Caspase-3 |
| title | Effect of concomitant use of pitavastatin with neoadjuvant chemotherapy protocols in breast cancer patients: A randomized controlled clinical trial |
| title_full | Effect of concomitant use of pitavastatin with neoadjuvant chemotherapy protocols in breast cancer patients: A randomized controlled clinical trial |
| title_fullStr | Effect of concomitant use of pitavastatin with neoadjuvant chemotherapy protocols in breast cancer patients: A randomized controlled clinical trial |
| title_full_unstemmed | Effect of concomitant use of pitavastatin with neoadjuvant chemotherapy protocols in breast cancer patients: A randomized controlled clinical trial |
| title_short | Effect of concomitant use of pitavastatin with neoadjuvant chemotherapy protocols in breast cancer patients: A randomized controlled clinical trial |
| title_sort | effect of concomitant use of pitavastatin with neoadjuvant chemotherapy protocols in breast cancer patients a randomized controlled clinical trial |
| topic | Synergistic action Tumor response Ki67 Hormone receptor Cyclin D1 Caspase-3 |
| url | http://www.sciencedirect.com/science/article/pii/S1319016422002031 |
| work_keys_str_mv | AT samaradewidar effectofconcomitantuseofpitavastatinwithneoadjuvantchemotherapyprotocolsinbreastcancerpatientsarandomizedcontrolledclinicaltrial AT omarhamdy effectofconcomitantuseofpitavastatinwithneoadjuvantchemotherapyprotocolsinbreastcancerpatientsarandomizedcontrolledclinicaltrial AT ahmedeltantawy effectofconcomitantuseofpitavastatinwithneoadjuvantchemotherapyprotocolsinbreastcancerpatientsarandomizedcontrolledclinicaltrial AT mohamedelmesery effectofconcomitantuseofpitavastatinwithneoadjuvantchemotherapyprotocolsinbreastcancerpatientsarandomizedcontrolledclinicaltrial AT amalmelgayar effectofconcomitantuseofpitavastatinwithneoadjuvantchemotherapyprotocolsinbreastcancerpatientsarandomizedcontrolledclinicaltrial AT moetazamsoliman effectofconcomitantuseofpitavastatinwithneoadjuvantchemotherapyprotocolsinbreastcancerpatientsarandomizedcontrolledclinicaltrial |